Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 9

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 9
---
, as amended (the “Securities Act”) in reliance on Section 4(a)(2) of the Securities Act and may not be offered or sold by the holders of those shares absent registration or an applicable exemption from the registration requirements. As a general matter, holders of such shares will not be able to transfer any of their shares until at least six months after receiving shares of MIRA Common Stock, which is when the shares would first be eligible to be sold under Rule 144 promulgated under the Securities Act, assuming the conditions thereof are otherwise satisfied.

Q: What will MIRA’s stockholders receive in the Merger?

A:At the Effective Time, MIRA’s stockholders will continue to own and hold their existing shares of MIRA Common Stock.

Q: What will happen to MIRA’s options and restricted stock units in the Merger?

A: MIRA stock options and MIRA restricted stock units will remain outstanding and will not change in connection with the Merger.

Q: Who will be the directors of MIRA following the Merger?

A:At the Effective Time, the post-Merger company is expected to initially consist of four (4) of the five (5) current members of MIRA’s board of directors, comprised of Erez Aminov, Edward MacPherson, Matthew Whalen and Matthew del Guidice, with MIRA’s other current director, Denil Shekhat, being replaced with Kelly Stackpole, SKNY’s current CEO, each until their respective successors are duly elected or appointed and qualified or their earlier death, resignation or removal.

The aforementioned board of directors will have an audit committee, a compensation committee and a nominating and corporate governance committee, in accordance with the rules of The Nasdaq Stock Market LLC (“Nasdaq”).

Q: Who will be the executive officers of MIRA following the Merger?

A:Immediately following the Merger, the executive management team of the post-Merger company is expected to remain the same as MIRA pre-Merger:

| Name         |     | Position          
 with MIRA         |
| Erez         
 Aminov       |     | Chief             
 Executive Officer |
| Alan         
 Weichselbaum |     | Chief             
 Financial Officer |

| 2 |

Q: As a stockholder of MIRA, how does MIRA’s Board of Directors (“MIRA Board”) recommend that I vote?

A:After careful consideration, the MIRA Board unanimously recommends that the holders of MIRA Common Stock as of